US EditionSACHI Trial Results: Savolitinib-Osimertinib Combo Improves PFS in MET-Amplified EGFR-Mutated NSCLC - ILCN.org (ILCN/WCLC)
Summary by ILCN.org (ILCN/WCLC)
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
SACHI Trial Results: Savolitinib-Osimertinib Combo Improves PFS in MET-Amplified EGFR-Mutated NSCLC - ILCN.org (ILCN/WCLC)
MET amplification is a key resistance mechanism in more than 20% of pretreated EGFR-mutant non-small cell lung cancer (NSCLC) cases. It’s also tied to early disease progression and poor prognosis. Shun Lu, MD, PhD Biomarker-guided treatment options after progression on EGFR-tyrosine kinase inhibitor (TKI) therapy remain limited. Until recently, no randomized study has addressed the role of targeted therapies for MET-amplification in this clinic…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
